



Published in final edited form as:

Nature. 2022 June ; 606(7914): 570–575. doi:10.1038/s41586-022-04766-2.

## Generation of specialized blood vessels via lymphatic transdifferentiation

Rudra N. Das<sup>1,\*</sup>, Yaara Tevet<sup>1</sup>, Stav Safriel<sup>1</sup>, Yanchao Han<sup>2,3</sup>, Noga Moshe<sup>1</sup>, Giuseppina Lambiase<sup>1</sup>, Ivan Bassi<sup>1</sup>, Julian Nicenboim<sup>1</sup>, Matthias Brückner<sup>4</sup>, Dana Hirsch<sup>5</sup>, Raya Eilam-Altstadter<sup>5</sup>, Wiebke Herzog<sup>4</sup>, Roi Avraham<sup>1</sup>, Kenneth D. Poss<sup>2</sup>, Karina Yaniv<sup>1,\*</sup>

<sup>1</sup>. Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel

<sup>2</sup>. Duke Regeneration Center, Department of Cell Biology, Duke University School of Medicine, Durham, United States

<sup>3</sup>. Institute for Cardiovascular Science, Medical College, Soochow University, Suzhou, China

<sup>4</sup>. University of Muenster and Max Plank Institute for Molecular Biomedicine, Muenster, Germany

<sup>5</sup>. Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel

### Abstract

The lineage and developmental trajectory of a cell are key determinants of cellular identity. In the vascular system, endothelial cells (ECs) of blood and lymphatic vessels (LVs) differentiate and specialize to cater the unique physiological demands of each organ<sup>1,2</sup>. While LVs were shown to derive from multiple cellular origins, lymphatic ECs (LECs) are not known to generate other cell-types<sup>3,4</sup>. Here, we use recurrent imaging and lineage-tracing of ECs in zebrafish anal fins (AF), from early development through adulthood, to uncover an unexpected mechanism of specialized blood vessel formation through transdifferentiation of LECs. Moreover, we demonstrate that deriving AF vessels from lymphatic vs. blood ECs results in functional differences in the adult organism, uncovering a link between cell ontogeny and functionality. We further use scRNA-seq to characterize the different cellular populations and transition states involved in the transdifferentiation process. Finally, we show that akin to normal development, the vasculature is re-derived from lymphatics during AF regeneration, demonstrating that LECs in adult fish retain both potency and plasticity for generating blood ECs. Overall, our work highlights a new innate mechanism of blood vessel formation through LEC transdifferentiation, and provides *in vivo* evidence for a link between cell ontogeny and functionality in ECs.

\* Corresponding Authors **Karina Yaniv** Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 76100, Israel, karina.yaniv@weizmann.ac.il, **Rudra N. Das** Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 76100, Israel, rudra-nayan.das@weizmann.ac.il.

#### Author contributions

R.N.D designed and conducted experiments, analysed data, and co-wrote the manuscript; I.B., N.M., G.L., and Y.T. conducted experiments and data analyses; S.S. and Y.T. performed bioinformatics analyses; M.B. and J.N. generated transgenic lines; Y.H. and K.D.P. generated knockin zebrafish and analyzed data; D.H. and R. E.-H. assisted with smFISH experiments; W.H. provided transgenic lines; R.A. supervised scRNASeq data analyses; K.Y. directed the study, designed experiments, analyzed data and co-wrote the paper with inputs from all authors.

The authors declare no competing interests.

Through lifetime, blood and lymphatic vessels acquire distinct organotypic specializations to properly serve the organ needs<sup>1,2</sup>. Here, we focus on the zebrafish anal fin (AF) (Fig. 1a), an adult-specific structure established during metamorphosis<sup>5,6</sup> (Fig. 1a,a'), which is vascularized by secondary vessels (SVs)- a specialized blood vessel type carrying intermittent erythrocyte flow<sup>7-9</sup>. While extensive work has been devoted to understand the physiology of this peculiar blood vessel type<sup>10,11</sup>, their origins, molecular features and specialization mechanisms, remain unexplored<sup>12</sup>.

To study the formation of the AF vasculature, we used Tg(*mrc1a:egfp*); (*prox1aBAC:KalTA4-4xUAS-E1b:uncTagRFP*) reporters, whose co-localization labels *bona fide* lymphatic vessels (Extended Data Fig. 1a-e'), in combination with Tg(*kdr1:BFP*), thereby enabling simultaneous examination of the lymphatic (*mrc1a+;prox1a+*) and blood (*kdr1+;prox1a-*) vessel components (Extended Data Fig. 1f-f'). In parallel, we tracked bone formation in Tg(*osx:mCherry*) fish. Using recurrent imaging of individual animals between 15-30 dpf, we defined four stages of AF vascular formation (Extended Data Fig. 1g-j; Table 1). At Stage 0, before AF appearance, the median fin fold area is devoid of ECs (Fig. 1b). As AF development begins (Extended Data Fig. 1g), lymphatic sprouts arising from the thoracic duct (TD) and the cardinal collateral lymphatic vessel (CCL)<sup>13</sup> enter the anterior and posterior poles of the AF (Stage I, Fig. 1c; Extended Data Fig. 1k) and merge to form a lymphatic arc (Fig. 1c'; Extended Data Fig. 1k'). Concomitantly, *kdr1:BFP+* sprouts from the posterior cardinal vein (PCV) and cloacal (cl) blood vessels, penetrate the AF as well (Fig. 1c,c'; Extended Data Fig. 1k,k'). As the fin rays elongate (Fig. 1d,e; Extended Data Fig. 1h,i), the Lymphatic Vascular Component (LVC) of the AF ramifies (Stage II, Fig. 1f, Extended Data Fig. 1l) and grows along the developing bones (Stage III, Fig 1g-h'; Extended Data Fig. 1m). Conversely, the Blood Vascular Component (BVC) remains restricted to the dorso-anterior area (Fig. 1f,g; Extended Data Fig. 1l,m). Similar mechanisms underlie the formation of the Dorsal Fin (DF) that develops at comparable stages (Extended Data Fig. 1n-n'). The notable prevalence of the LVC over the BVC in the developing fins (Fig. 1i) is striking, given that in most cases, lymphangiogenesis lags behind blood vessel growth<sup>2,13-15</sup>.

Multiple lines of evidence support the lymphatic identity of these vessels. First, they are directly connected to trunk lymphatics (Extended Data Fig. 2a-a"; Supplementary Video 1) and besides *prox1a* and *mrc1a*, they express also Tg(*lyve1b:dsRed*) (Extended Data Fig. 2b-d). In addition, *prox1a* mRNA expression was specifically detected in the *mrc1a:GFP+* LVC, but not in *kdr1:GFP+* BVC, whereas pan-endothelial *fli1a* mRNA puncta were observed in all vessels (Extended Data Fig. 2e-j). Finally, the lymphatic vs. blood vessel identity was functionally confirmed through time-lapse imaging of Tg(*gata1a:dsRed*) that showed erythrocyte flow only in BVC vessels (Supplementary Video 2), and by Qdot705 angiography<sup>16</sup> that resulted in sole *kdr1+* BVC labeling (Fig. 1j,j'). Hence, our anatomical, molecular and functional analyses demonstrate that the development of the AF is specifically associated with lymphatic, rather than blood vessel growth.

We wondered why, in spite of the presence of conventional blood vessels near the AF (e.g., PCV, BVC), the tissue utilizes a lymphatic source for vascularization. One potential outcome of such unusual mechanism would be the creation of a local hypoxic environment,

largely regarded as key for chondrogenesis and osteogenesis<sup>17</sup>, while enabling delivery of factors required for bone formation and growth. Indeed, when calcein was injected subcutaneously<sup>16,18,19</sup> in the anterior trunk, it rapidly reached the lumen of the AF lymphatics, developing bones and associated mesenchyme (Extended Data Fig. 2k–k’), suggesting that the initial LVC delivers solutes to the AF while maintaining a hypoxic microenvironment (Extended Data Fig. 2,l,l’).

Strikingly, as AF growth proceeds, the expression of lymphatic markers is lost along the fin rays (Stage IV, Fig. 1k; Extended Data Fig. 2m,n). This reduction was not due to vessel pruning or retraction, as all fin vessels were detected in Tg(*fl1a:dsRed*) adult animals albeit with no lymphatic marker expression (Fig. 1l,m; Extended Data Fig. 2o). Moreover, intravascular injection of Qdot705 indicated that the adult AF vessels are fully lumenized and connected to blood circulation (Extended Data Fig. 2p,p’), suggesting they have acquired a blood vessel fate.

To investigate whether the AF plexus forms via transdifferentiation of the initial lymphatic network, we established a conditional EC-specific multicolor lineage tracing system (Extended Data Fig. 3a,b) (referred as ‘*flibow*’) and used multispectral confocal imaging to obtain the ‘spectral signature’ of individual ECs (Extended Data Fig. 3c–j’). We induced recombination at 2.5 dpf, selected *Larvae* with differentially labeled trunk lymphatics at 6–10 dpf (prior to AF formation), and imaged them separately, every 2–4 days, to trace the formation of the AF vasculature (Table 2). As seen in sequential images of the same animal (Fig. 2a–e), we detected distinctly labelled TD and sprouts of matching clonal identity (green), penetrating the AF (Fig. 2a,b), generating the Stage II plexus (Fig. 2c) and growing along the bones (Fig. 2d,e). When extended through adult stages, our analyses indicated that the entire AF vasculature is derived from a few LECs colonizing the early AF (Fig. 2f,g). Overall, uniquely labeled clones in mature fin ray vessels, were traced back to Stage I/II lymphatic-derived sprouts of identical colors, in 95% AFs (Table 2 and Extended Data Fig. 4a). Moreover, no contribution of labeled BVC clones was detected in 98% of analysed AF ray vessels and no new colors were observed in ~94% of the cases (Table 2 and Extended Data Fig. 4a–c’).

To further test lineage relationships, we devised two alternative strategies. First, we generated Tg(*kdrl:CreER<sup>T2</sup>;flibow*) fish, where the *flibow* construct is activated only in blood ECs<sup>20</sup>. In addition, we established a *flibow*-independent system, by combining Tg(*kdrl:CreER<sup>T2</sup>*) with Tg(*bactin2:loxP-BFP-loxP-DsRed*)<sup>21</sup> fish. In both cases, upon induction of *kdrl:CreER<sup>T2</sup>* mediated recombination, 100% of the labeled clones found in the AF, were restricted to the BVC (Extended Data Fig. 4d–f’), and never found in the AF ray vessels. Overall, our results using multiple lineage tracing strategies demonstrate that the whole mature AF plexus originates from *bona fide* LECs, with no contribution from neighboring blood vessels.

Notably, while lymphatics originate from multiple sources<sup>3,4</sup>, the LEC fate was shown to be “reprogrammable” only due to mutations or other insults<sup>22–25</sup>. In contrast, there is no evidence of an innate program that utilizes differentiated LECs to generate blood vessels. To ascertain the molecular nature of this vessel fate-switch, we analyzed publicly available

RNA-seq data from *PROX1* downregulated-Human Dermal Lymphatic Endothelial Cells (HDLECs)<sup>26</sup>. In this setting, loss of lymphatic fate correlated with significant upregulation of well-known blood vessel markers such as *KDR*, *FLT1*, *DLL4* and *SOX17* (Extended Data Fig. 5a,b). Taking cues from this dataset, we assessed the expression of *sox17*, a transcription factor enriched in mammalian arteries<sup>27</sup>, and found *sox17<sup>EGFP</sup>*-labeled ECs in the developing ray vessels, from stage II onwards (Fig. 2h–k and Extended Data Fig. 5c–g). Similarly, around Stage II, a few LECs within the plexus turn on expression of *Tg(flt1\_9a:GFP)* (Fig. 2l–l’), a *flt1* enhancer that labels angioblasts and arteries, but not differentiated LECs<sup>28–30</sup> (Extended Data Fig. 5h,h’). As the rays grow, additional *lyve1b+/-prox1a+* LECs upregulate *flt1\_9a:GFP* (Extended Data Fig. 5i–j’) and *kdr1:GFP* (Extended Data Fig. 5l–m’), indicating their progressive transition toward a less differentiated state. Of note, the pattern of expression driven by the *flt1\_9a* enhancer was different from that of the *flt1* transcript, which was found to be enriched only in the BVC (Extended Data Fig. 5k).

To globally resolve the heterogeneity of ECs generated during the transition, we carried out single-cell RNA sequencing (scRNA-seq)<sup>31</sup> on ECs isolated from *Tg(fli1a:dsRed)* AFs at stages II–III, when the transdifferentiation process takes place. Five clusters (Fig. 2m) were annotated based on their differentially expressed genes (DEGs) (Fig. 2n and Table 3). The BVC cluster (purple) featured significant expression of known blood EC markers, such as *cdh5*, *flt1* and *kdr1* (Fig. 2n,o and Extended Data Fig. 6a). ECs of the LVC were annotated to 3 different groups: (i) differentiated LECs (LEC, blue), enriched with lymphatic markers such as *prox1a*, *lyve1b* and *mrc1a* (Fig. 2n,o and Extended Data Fig. 6b); (ii) LVC1 (green), characterized by expression of *sox17* and additional BV markers like *hey1* and *dll4* (Fig. 2n,o and Extended Data Fig. 6c), represents the LVC-derived blood vessels; and (iii) LVC2 (red), with no clear lymphatic or blood EC signature (Fig. 2n,o). Since the transdifferentiation process involves only the LVC derivatives (LEC, LVC1 and LVC2), we re-analysed these clusters. PHATE<sup>32</sup> map (Fig. 2p), as well as Slingshot<sup>33</sup> and PAGA<sup>34</sup> analyses (Extended Data Fig. 6d,e), suggest LVC2 to be an intermediate population, with lymphatic marker expression gradually decreasing from LEC to LVC2 (Extended Data Fig. 6f), and blood EC gene expression increasing from LVC2 to LVC1 (Extended Data Fig. 6g). Interestingly, LVC2 features genes associated with chromatin binding and remodeling, nucleosome organization and DNA packaging (Fig. 2n,o) such as *seta*<sup>35</sup>, *hmgb*, *hmgn*<sup>36,37</sup> and *prmt1*<sup>38</sup>, shown to be enriched in undifferentiated/progenitor cells and downregulated across cell differentiation. Thus, the LVC2 signature bodes well with the idea that it represents a population of transitioning/differentiating cells.

Our imaging and scRNA-seq analyses highlight the unique expression of *Sox17* in transdifferentiating ECs. To interrogate the role of *Sox17* in suppressing the LEC fate, we injected *UAS:Sox17* DNA into *Tg(hsp70l:Gal4;lyve1b:dsRed)* embryos. Heat-activation at 21 dpf rendered 25.24±8% of injected fish displaying patches of missing *lyve1b* expression in the AF (Extended Data Fig. 7a–b’). Moreover, mosaic overexpression of *Sox17* in ECs, resulted in absence or incomplete formation of the TD in 17.94% of the injected embryos (Extended Data Fig. 7c–g). Together these results demonstrate that ECs in the developing AF progressively lose LEC identity while gaining expression of BEC markers, and point to *Sox17* as potential key player in this transition.

Previous work described LEC reprogramming by blood flow shear stress<sup>24</sup>. To check whether the transdifferentiation precedes the exposure of the AF vessels to blood flow, or is rather the presence of blood flow what leads to transdifferentiation, we injected fluorescent tracers intravascularly, at various timepoints, and followed their distribution in the fin vessels *vis a vis* marker analysis. We found that while the fluorescent tracers remain restricted in the BVC in Stage II AFs (Fig. 3a,a'), they enter the lumen of the LVC-derivatives in Stage III AFs (Fig. 3b,b' and Extended Data Fig. 8a–b'), indicating that patent connections with the systemic circulation were established. Notably, both *sox17<sup>EGFP</sup>* (Fig. 3c,c') and *flt1\_9a* (Extended Data Fig. 8c,c') expression was detected in transdifferentiating ECs before exposure of the vessels to blood flow. Imaging of *sox17<sup>EGFP</sup>;lyve1b:dsRed* and *sox17<sup>EGFP</sup>;fli1a:dsRed* revealed that the connection with blood circulation is established through a “bottom-up” mechanism whereby the newly generated *sox17<sup>EGFP</sup>*+ vessels extend dorsally and anastomose with sprouts arising from the dorsal aorta (DA) (Fig. 3d and Extended Data Fig. 8d–g"). Accordingly, *flibow* lineage tracing showed that the connecting vessels arise in the AF and are LVC-derived (Extended Data Fig. 8h). Altogether, our results support the idea that LEC transdifferentiation is not elicited by blood flow.

Given that the fin ray vessels are LVC derived, we turned to *flt4<sup>-/-</sup>* animals, which lack most lymphatic vessels<sup>39,40</sup> (Extended Data Fig. 9a,a') to investigate how LEC absence would impact fin formation. Surprisingly, we found that blood, and not lymphatic vessel sprouts, generate the entire vascular network in the developing AF (Fig. 3e–h) and DF (Extended Data Fig. 9b–e) of *flt4<sup>-/-</sup>* animals, whereas the LVC is missing in both fins. Similarly, when lymphatics were ablated using the NTR/MTZ system<sup>41</sup>, *kdr1+* BVC sprouts contributed substantially to ray vessel formation (Fig. 3i and Extended Data Fig. 9f–h). To genetically confirm the alternative origin of the ray vessels in *flt4<sup>-/-</sup>*, we used the *flibow* system. Extended Data Fig. 9i depicts a representative *flibow;flt4<sup>-/-</sup>* fish with a single sprout connected to the PCV and cl blood vessels, colonizing the AF. ECs of matching clonal identity are later detected in the ray vessels of the mature AF (Extended Data Fig. 9j). Thus, unlike WT animals, *flt4<sup>-/-</sup>* mutants possess an AF plexus that is fully derived from pre-existing blood vessels.

During embryonic development, several cell types are known to originate from more than one source. However, to what extent the ontogeny of a cell is linked to its function in the adult organism, remains an open question. Notably, WT and *flt4<sup>-/-</sup>* animals provide a unique opportunity to assess the functionality of vessels arising from different sources, in the same organ. Before all else, we noticed that *flt4<sup>-/-</sup>* AFs present unusual blood pooling and erythrocyte accumulation that were not detected in WT siblings (Fig. 3j,j'). By recording erythrocyte flow, we found that mature WT AFs display an unusual pattern of ‘intermittent’ flow, as previously reported<sup>8,10,11</sup>, whereas *flt4<sup>-/-</sup>* AF vessels presented continuous blood flow and high erythrocyte density both in juvenile and adult stages (Extended Data Fig. 10a–e; Supplementary Video 3,4). Likewise, we detected higher *gata1a:dsRed+* erythrocyte content in the ray vessels of *flt4<sup>-/-</sup>* mutants (Extended Data Fig. 10f–i).

To ascertain whether the mutant's vessel and flow properties affect AF bone formation, we used micro-computed tomography ( $\mu$ CT)<sup>42</sup>. Analysis of *flt4<sup>-/-</sup>* revealed prominent malformations, particularly in the medial radials, which were significantly shorter and

less structured than those of WT counterparts (Fig 3k; Extended Data Fig. 10j–l). Thus, the different origin of the AF vasculature in *flt4*<sup>-/-</sup> animals leads to malformations in the skeletal structures. Altogether our results indicate that the functional properties of the mature AF vasculature are directly linked to the source of its ECs (blood vs. lymphatic), highlighting the importance of cell “biography” for proper tissue development and functionality.

We next asked whether the transdifferentiation process is recapitulated during regeneration. Certainly, resection of the AF in adult fish (Fig. 4a) triggered sprouting from the unamputated lymphatics (Fig. 4a',b). These new LEC sprouts extended ventrally, wrapping the regenerating bones, first as a disorganized plexus and later on establishing the well-ordered vessel pattern akin to the developmental process (Extended Data Fig. 11a–b). The transdifferentiation was also fully recapitulated, as reflected by gradual appearance of *sox17*<sup>EGFP</sup> and *flt1\_9a*:GFP (Fig. 4c; Extended Data Fig. 11c), and loss of lymphatic markers (Fig. 4d,e). To substantiate these findings, we lineage traced ECs before AF resection and following regeneration in the same animal. We found that ECs in the regenerated AFs were clonally related to the LECs that established the original AF plexus, and no new clones were detected in 32/34 regenerated fin rays (Extended Data Fig. 10d–f). In addition, following *kdr1:CreERT;flibow* induction all labeled clones within the regenerated AF, were located in the BVC (Extended Data Fig. 11g), confirming that pre-existing blood vessels do not give rise to the AF plexus during regeneration. Finally, we tracked the lineage history of the AF vasculature in the same animal, from development through adulthood, and following regeneration (Fig. 4f). As expected, we found that ECs clonally related to the LECs that generated the initial LVC-derived plexus, populate the regenerating fins (Fig. 4g–k), illuminating for the first time the lifetime and regenerative lineage history of ECs composing a vascular plexus. Of note, the use of zebrafish helped circumvent some of the intrinsic limitations associated with lineage tracing in mammals<sup>43</sup>, and enabled tracing the lineage history of ECs and their progenies throughout the lifetime of a single organism. Taken together our results indicate that AF regeneration re-activates the LEC-to-BEC transdifferentiation program observed during metamorphosis, reinforcing the importance of this mechanism for generating a proper bone-associated vasculature. Moreover, these findings indicate that LECs harbor the plasticity to give rise to blood vessels through life.

Overall, our work highlights a new mechanism of specialized blood vessel formation through LEC transdifferentiation, and provides *in vivo* evidence for a link between cell ontogeny and functionality of ECs. In addition, our findings help solve a long-standing controversy regarding the existence of lymphatics and SVs in teleosts<sup>44</sup>. By showing that the AF/DF vessels are in fact lymphatic-derived, we demonstrate not only that both vessel types exist in teleosts, but also that the latter do not form in the absence of lymphatics. We further provide compelling evidence demonstrating that the SVs represent a specialized blood vessel type with unique functional and molecular properties that, as other organotypic vascular beds, evolved to serve the specific needs of teleost appendages. Finally, our findings provide new insights into our current understanding of lymphatic plasticity and diversification, contributing to a growing body of literature revealing exciting new roles for lymphatic vessels<sup>45–51</sup>.

## Materials and Methods

### Zebrafish husbandry and transgenic lines

Zebrafish were raised by standard methods and handled according to the guidelines of the Weizmann Institute Animal Care and Use Committee<sup>28</sup>. The *Tg(lyve1b:dsRed)<sup>nz101</sup>*<sup>29</sup>, *Tg(fli1ep:dsredex)<sup>um13</sup>*<sup>30</sup>, *Tg(flt1\_9a:EGFP)<sup>wz2</sup>*<sup>29</sup>, *Tg(mrc1a:EGFP)<sup>y251</sup>*<sup>13</sup>, *TgBAC(prox1a:KALTA4,4xUAS-E1B:TagRFP)<sup>nim5</sup>*<sup>29</sup>, *flt4<sup>um203/um203</sup>*<sup>39</sup>, *Tg(kdrl:EGFP)<sup>s843</sup>*<sup>52</sup>, *Tg(kdrl:TagBFP)<sup>mu293</sup>*<sup>53</sup>, *Tg(osx:mCherry)<sup>zf131</sup>*<sup>54</sup>, *Tg(hsp70l:Gal4vp16)<sup>vu22</sup>*<sup>55</sup>, *Tg(kdrl:Cre-ERT<sup>2</sup>)<sup>fb13</sup>*<sup>20</sup>, *Tg(UAS:NTR-mCherry)<sup>56</sup>*, *TgBAC(flt1:YFP)<sup>hu4624</sup>*<sup>57</sup>, *Tg(bactin2:loxP-BFP-loxP-DsRed<sup>21</sup>* and *Tg(fli1a:Gal4FF)<sup>ubs3</sup>*<sup>29</sup> were previously described.

Experiments were conducted on fish from the same clutch. Fish were initially selected based on their size (~5.2 mm for Stage I initiation) and were subsequently staged based on criteria described in Table 1, and Extended Data Fig. 1g–j. For regeneration experiments, animals were selected by age (3–6 mpf). For imaging, we used either *casper* (*roy<sup>-/-</sup>; nacre<sup>-/-</sup>*)<sup>58</sup> background, or the embryos were treated for 6 days with 0.003% N-phenylthiourea (PTU) (Sigma, St Louis, MO) to inhibit pigment formation.

### Generation of transgenic lines

The *Tg(fli1a:Brainbow1.0L)<sup>mu254</sup>* (*fliBow*) fish was generated by cloning the CMV-Brainbow-1.0 L construct (Addgene #18721) downstream to the *fli1a* promoter<sup>59</sup>, into a plasmid containing *tol2* sites. The *Tg(hsp70l:CreER<sup>T2</sup>)* line was established by fusing the coding sequence of *CreER<sup>T2</sup>* downstream of the heat-inducible promoter – *hsp70l*<sup>60</sup>. The *Tg(prox1a:Gal4)* line was generated using BAC DKEY-5J3 (BioScience, Cat no. HUKGB735J035Q) through transposon mediated BAC transgenesis<sup>61</sup>. All plasmids were generated using the Gateway system as described<sup>59</sup>.

The *sox17<sup>EGFP</sup>* knock-in line (allele pd305) was generated by TALEN-mediated targeted knock-in through non-homologous end joining. Briefly, an obligate heterodimeric TALEN pair (left arm: 5'-GATCAATAAGGATACGC-3', right arm: 5'-CGGGACTGCTCATCTC-3') was assembled as described<sup>62</sup> to induce a double strand break at the start codon region of the *sox17* gene. The donor vector has the same structure as described<sup>63</sup> except that the TALEN sequences were replaced with the *sox17* right arm and another left arm (5'-GTATACTACTGCGGCTAT-3') upstream of the EGFP-polyA cassette. Vector-free knock-in line was generated by co-injection of the TALEN mRNAs, donor vector and *flp* mRNA at one-cell stage.

### Flibow induction

To achieve efficient labelling of trunk lymphatics induction of Cre recombinase in *fliBow* embryos was carried out at 2.5 dpf (60 hpf). First the embryos were pre-heated at 36°C for 15 mins for triggering *hsp70l* mediated Cre expression. Then they were subjected to combined heat (36°C) and 5µM 4-hydroxytamoxifen (diluted in E3 medium) treatment for 45mins. Upon completion of the treatment, embryos were washed three times in fresh E3 medium and returned to fresh water. Fluorescence from the 'switched' cells was readily

detectable ~24 hours post-treatment (Extended Data Fig. 3h–j'), and remained stable in ECs and their progenies for the entire experimental period (Extended Data Fig. 3j,j'). While the heat and 4-OHT treated progenies displayed ECs with diverse spectral signatures, siblings exposed to either treatment alone, contained only tdTomato-expressing ECs both in larval and adult stages (Extended Data Fig. 3d–g). Selected animals were imaged at the appropriate AF development stages days and returned back to fresh water until the endpoint of the experiment. For triggering *kdr1:CreER<sup>T2</sup>* mediated Cre expression, embryos were treated only with 5µM 4-hydroxytamoxifen between 3.5–5.5 dpf.

### Sox17 overexpression

The *UAS-sox17* constructs were generated by amplifying the coding sequences of *sox17* (NM\_131287.2) with the following primers:

*sox17*F: 5' - atgagcagtcgccgatgcg -3'

*sox17*R: 5' -tcaagaattattatagccgcagt -3'

The resulting *sox17* fragment was then cloned downstream of UAS using Gateway cloning. The *UAS:sox17* construct was injected in *Tg(fli1a:Gal4;lyve1b:dsRed)* or *Tg(hsp70l:Gal4;lyve1:dsRed)* embryos at 1-cell stage. Heat shock was carried out at 37°C for 1h on 21dpf *Tg(hsp70l:Gal4;lyve1:dsRed)* animals (for juvenile induction).

### NTR-MTZ mediated cell ablation

Nitroreductase-Metronidazole (NTR-Mtz) mediated cell ablation protocol was modified from<sup>41</sup>. Since *prox1a:Gal4; UAS NTR-mCherry* is expressed in many tissues, Mtz treatment beyond 4hrs at concentrations above 5mM were lethal. We developed a low dose multi-treatment protocol, that allowed partial ablation of lymphatics on day 1, followed by blocking of lymphatic regrowth through 4 more low-dose treatments every two days. This allowed us to observe the AF for 15–25 days post the first treatment. However, the animals did not survive till adulthood. Briefly, Mtz was diluted in E3 medium to a final 4mM concentration and 16–18 dpf *prox1a:Gal4; UAS NTR-mCherry larvae*, were soaked in it for 2.5hrs. Following washing and recovery, animals were treated again with 4mM Mtz for 1hr every two days.

### Anal fin regeneration

Adult fish (between 3–6 mpf) were anesthetized by immersion into 0.04% tricaine (Sigma, St Louis, MO) and the AF were carefully detached using surgical blade and forceps. The animals were immediately allowed to recover in fresh water.

### Angiography and lymphatic uptake assays

Angiography was performed on anesthetized *larvae* and juvenile animals, by injecting Qtracker705 (Invitrogen, Q21061MP), Tetramethylrhodamine Dextran (2,000,000 MW) (ThermoFisher, D7139) and Fluorescein isothiocyanate (FITC) Dextran (500,000 MW) (Sigma, 46947) into the heart using microinjection glass capillaries, as described<sup>18</sup>. In adults, heart was accessed in anesthetized animals through a small incision, followed by



microinjection of Qtracker705<sup>28</sup>. In both cases, imaging was initiated within 5 mins of the injection and the animals were euthanized immediately afterwards. For lymphatic uptake, Calcein (Sigma) was injected subcutaneously<sup>16</sup> in the trunk (above the gut). Imaging was initiated 15 mins after the injection.

### Hypoxyprobe Staining

For assessment of hypoxia, Hypoxyprobe kit (Hypoxyprobe, Inc.) was used. The staining protocol was performed through modification of previous work in zebrafish<sup>64</sup>. Briefly, zebrafish of ~17–20 dpf were injected intramuscularly with 30 nl of 10 mg/ml pimonidazole solution (Hypoxyprobe, Inc.). Injections were performed in the trunk area, dorsal to the AF for 3 consecutive days. In the sham injected animals, PBS was injected in the same amount and frequency as the test animals. Following this, the animals were euthanized and the AF was fixed in 4% PFA. Whole-mount immunohistochemistry was performed through standard protocol. The samples were stained with 4.3.11.3 mouse Mab at a dilution of 1:50.

### Single molecule fluorescent *in situ* hybridization (smFISH)

The construction of the probe library, hybridization procedure and imaging conditions were previously described<sup>65</sup>. In brief, probe libraries were designed using the Stellaris FISH Probe Designer (Biosearch Technologies, Inc., Petaluma, CA). Both *prox1a* and *fli1a* library consisted of 48 probes, each of 20 bps length, complementary to the coding sequence of the gene (Table 4), and was coupled to Cy5 (GE Healthcare, PA25001) and Alexa Fluor 594 respectively. As a modification of the standard tissue smFISH protocol, whole mount zebrafish AFs were fixed in cold 4% PFA for 30 minutes and washed twice with PBS containing 0.3% Triton X-100 (Sigma) for 5 min, followed by cold 70% ethanol for 2.5 h. The samples were then washed in 2XSSC and incubated for 10 min with Proteinase K solution at 37°C. The next steps were performed as described<sup>65</sup>. Formamide concentration of the wash and hybridization buffers was increased to 25%. Additionally, the pre-incubation with the wash buffer was extended to 90 minutes. Slides were mounted using ProLong Gold (Molecular Probes, P36934) and imaged on a Nikon-Ti2-E inverted fluorescence microscope with 100x or 60x oil-immersion objectives connected to iXon Ultra 888 CCD camera (Andor, Oxford Instruments), using Nikon NIS Advance Elements software.

### Microscopy and imaging

Confocal imaging was performed using Zeiss LSM780 or LSM880 upright confocal microscopes (Carl Zeiss, Jena, Germany) equipped with water immersed 20x NA 1.0 or 10x NA 0.5 objective lens. Euthanized animals were mounted using 1.5% w/v low melting agarose. For reiterative imaging of same animals, a custom-built chamber was utilized. z-stacks were acquired at 2–3  $\mu\text{m}$  increments. Larger images were acquired using tile-scanning, and the images were stitched using Imaris Stitcher 9.3 or Zeiss' Zen software.

*fibow* confocal imaging and lambda stack acquisition were performed by single, simultaneous scans (for each z-plane) with 458nm and 514nm single photon excitation lasers. Using Zeiss multichannel detector, the resulting emission spectra were collected into 11 channels, each detecting a range of 18nm from 454nm to 650nm, which encompassed emissions from all three fluorescent proteins of *fibow*.

Analysis of *fibow* images was performed by intensity measurement of each of the 11 channels for the selected ROIs (manually drawn to select single ECs). Normalized values of these intensities were plotted for different ECs for comparison. In certain cases, when ECs displayed similar intensity profiles and same origins, we averaged intensity values of these different ECs.

### Image processing

Confocal images were processed off-line using Fiji<sup>66</sup> version of ImageJ (NIH) or Imaris 9.3 (Bitplane). The images shown in this study are single-views, 2D-reconstructions, of collected z-series stacks. The colocalization channel was created using the Imaris 'Colocalization Module'. Co-localization thresholds were set manually.

*fibow* images were processed using Imaris 9.3. Each of the 11 channels were given RGB values that corresponded to the wavelength collected. Since many channels collect the emission from only one fluorescent protein, or detect noise (autofluorescence from rays and pigments), we chose 6 channels, leaving out those that were redundant or displayed a poor signal/noise ratio.

smFISH images were processed in Fiji. Background subtraction was performed using the rolling ball algorithm in Fiji. Abundance of RNA puncta within the vessels was calculated manually after selecting ROIs from the GFP (*mrc1a/kdr1*) channel. 3–5 ROIs per samples were selected to calculate number of puncta per unit area of the selected ROIs.

The 3D volume rendering was performed using Imaris 9.3 (Bitplane).

### Micro-computed tomography ( $\mu$ CT) and processing

$\mu$ CT was performed as described<sup>42</sup> with some modifications. Briefly, AFs from freshly euthanized wild-type and *flt4*<sup>-/-</sup> adult fish (4–5 mpf) were dissected, keeping the internal radials intact, and mounted on a 1ml pipette tip filled with 0.8% low melting agarose, with both ends sealed. The sample was placed in a sample holder and observed using Xradia 520 Versa (Zeiss), with an X-ray source of 40 kV and current 75  $\mu$ A. 2501 projections were scanned through 360° with 10s exposure time. The voxel size of the specimen was 2.03 $\times$ 2.03 $\times$ 2.03  $\mu$ m.

The scans were analyzed and segmented using Avizo 2019.4 software.

### AF erythrocyte flow analysis

Three ROIs were selected spanning different AF rays of each anesthetized juvenile or adult fish and 6 min time lapse images from a single z-plane were acquired. The imaging was performed using the transmitted light detector in the LSM880 confocal microscope, after manually determining the desirable contrast for each fin. The image size, zoom factor, pixel dwell time were kept constant for all experiments, allowing acquisition of images at a fixed frame interval of 0.152s.

The erythrocyte flux through the vessels was measured in Fiji. We plotted bright light intensity profile over time to reflect the state of erythrocyte flow. For this, a line ROI

was drawn across the lumen the vessel. Erythrocytes crossing this ROI caused fluctuations in the bright light intensity measured through this ROI. We determined the threshold of minimum intensity change that corresponds to passing of a single erythrocyte, and the number of events above this threshold were counted as erythrocyte-mediated intensity spikes and quantified in our ‘spike count’ plots.

### Bulk RNA-Seq analysis

To analyse RNA-seq raw counts data from <sup>26</sup>, we selected genes that were expressed in more than 2 samples, had at least 10 reads across all samples, and their mean expression was  $> 4$  for downstream analysis. R package DESeq2 (v1.26)<sup>67</sup> was used to normalize raw counts, perform regularized log<sub>2</sub> transformation (rlog) and identify differentially expressed genes (DEGs) across samples (p-value $<0.05$ ). In addition, lfcShrink function using apeglm estimation was used for shrink log<sub>2</sub> fold change (LFC) calculation, which allows to assess the expression changes in lowly expressed genes<sup>68</sup>.

### Single cell RNA-Seq experiments

**Cell collection**—Cells were isolated from 80 AFs of *Tg(fli1a:dsRed)*, and processed for single cell suspension. Briefly, tissues were manually chopped with a sterile razor followed by enzymatic dissociation using 2.5 ug/ml Liberase TM (Roche) diluted 1:5, incubated at 28°C for 25 minutes, manually pipetting every 5 minutes. Next, 2 volumes of Trypsin B (BI) and a dilution of 1:100 DNaseI (Roche) were added, followed by 7 minutes incubation at 28°C with manual pipetting. To stop the reaction, 3 volumes of 5% FCS were added. Cells were passed through a 70µm cell strainer and *dsRed+* cells were sorted by fluorescently activated cell sorter (BD FACS Aria III) into 384 barcoded well plates. Live-dead staining was performed using Sytox blue (Invitrogen).

**Library preparation, sequencing and pre-processing of single cell RNA-Seq data**—Plate-based single cell RNA sequencing libraries were processed using MARS-seq protocol, as previously described<sup>31,69</sup>. Sequence ready library was sequenced using Illumina NextSeq 500 to reach ~50,000 reads per cell. We sequenced 1036 cells from stage II/III AF. GRCz10 used for genome alignment. Data pre-processing was carried out following previously MARS-seq published protocols<sup>70–72</sup>. Cells with more than 1200 nFeatures (genes) were removed as suspected doublets; Cells with less than 200 nFeatures (genes) were removed for low coverage and cells with more than 25% mitochondrial gene content were removed for low quality. Overall, 632 cells passed quality filters for downstream analysis. Cells that passed quality filters contained a mean of 764 UMI counts and 492 genes per cell.

**Single-cell RNA-seq analysis**—We used Potential of Heat-diffusion for Affinity-based Trajectory Embedding (PHATE)<sup>32</sup> for all data normalization. `Library.size.normalize()` function was used, and square root transformation was applied. Using Seurat R package<sup>73</sup>, we selected 2000 most variable genes with the `FindVariableFeatures()` function. Data was scaled using `ScaleData()` function, with argument `vars.to.regress = ‘nCount_RNA’`. For downstream analyses we selected the first 25 principal components (PCs) and clustered the cells using the `FindClusters()` function, with a resolution parameter of 0.7. Iterations

of the resolution parameter from 0 to 1.2 to indicated cluster stability. Uniform Manifold Approximation and Projection (UMAP) analysis was applied for dimensionality reduction. Differentially expressed genes (DEGs) were detected using FindAllMarkers() function with default statistical parameters. Dotplot was created using DotPlot() function in Seurat R package. Dot color intensity represents the average expression level of a gene in a cluster. Dot size corresponds to the percentage of cells expressing the gene in the cluster. PHATE maps were obtained using the normalized data of the 3 clusters determining the transdifferentiation process (LECs, LVC1 and LVC2). Single genes were plotted on UMAP and PHATE maps and presented as imputed values of the raw data using Markov Affinity-based Graph Imputation of Cells (MAGIC)<sup>74</sup> with  $t = 2$  parameter. For PAGA, data was imported from Seurat object to Scanpy<sup>75</sup> using SeuratDisk R package. Nearest neighbors were computed using `sc.pp.neighbors()` function, with 25 PCs. PAGA graph was computed using `sc.tn.paga()` function with default parameters.

Trajectory inference was computed using Slingshot<sup>33</sup> R package on UMAP embeddings and cluster labels as determined by Seurat. `start.clus` parameter was set to LECs.


### Statistical Analyses

Statistical significance between two samples was calculated using the unpaired two-tailed Student's t-test assuming unequal variance from at least three independent experiments, unless stated otherwise. In all cases normality was assumed and variance was comparable between groups. Sample size was selected empirically following previous experience in the assessment of experimental variability. The investigators were not blinded to allocation during experiments and outcome assessment. Numerical data are the mean  $\pm$  s.e.m., unless stated otherwise. Statistical calculations and the graphs for the numerical data were performed using Prism 5 software (GraphPad Software, Incorporated, La Jolla, CA, USA). Statistical analyses for single cell and bulk RNA-Seq experiments are provided in the corresponding sections.

The datasets generated during and/or analysed during the current study are available in the GEO repository, [GSE197161](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE197161).

All illustrations and cliparts shown in Figures and Extended Data (except Fig. 1i) were obtained from Biorender


Extended Data



Extended Data Fig. 1: Morphological and molecular characterization of anal and dorsal fins formation.

a-d', *mrc1a:EGFP* and *prox1a:RFP* colocalization specifically highlights lymphatic vessels in zebrafish larvae. a, Bright-light image of 14 dpf zebrafish trunk, with boxes demarking dorsal (green), medial (red) and ventral (blue) areas depicted in b-d. b,c,d, show *prox1a* (red) and *mrc1a* (green) transgene expression, b',c',d' depict colocalization channel (yellow). e-e', intravascularly injected Qdot705 (cyan) are detected within blood vessels

but not in *mrc1a/prox1a* co-labelled lymphatics (yellow). f-f', Trunk blood and lymphatics vessels are differentially visualized in *kdr1:BFP;mrc1a:EGFP;prox1a:RFP* juvenile fish. *mrc1a/prox1a* colocalization (f') labels lymphatics, while *kdr1* highlights blood vessels (f', blue). g-j, Bright-light images of AF development with yellow arrowheads indicating important stage-specific features, such as mesenchyme condensation (g, arrowheads), appearance of rays (h, arrowheads), ray growth (i, arrowheads) and formation of joints (j, arrowheads). AF is first detected when the larva reaches ~5.2 mm in length (~15–17dpf). k-m, Triple *Tg(prox1a:RFP;mrc1a:EGFP;kdr1:BFP)* juvenile zebrafish, whose *prox1a:RFP;mrc1a:EGFP* colocalization channel is shown in Fig. 1c–g. n–n'', LVC mediated vascularization of DF. n, Schematic showing the position of the DF. n', n'', Confocal images of *Tg(prox1a:RFP;mrc1a:EGFP;kdr1:BFP)* animals show contribution of LVC and BVC during DF formation. n' shows all channels, n'' shows *prox1a:RFP;mrc1a:EGFP* colocalization channel along with *kdr1:BFP*. Scale bars, 20µm (e'), 30µm (b',c',d',f',g,k,k'), 50µm (h,i,l,m,n'), 100µm (j), 150µm (a). DL, Dorsal lymphatic, SL, Spinal lymphatic, DIL, Deep intersegmental lymphatic, TD, Thoracic duct, CCL, Collateral cardinal lymphatic, LL, Lateral lymphatic, SIL, Superficial intersegmental lymphatic.




### Extended Data Fig. 2: Molecular characterization of the AF vascular component.

a-a'', Confocal image of *Tg(mrc1a:GFP;prox1a:RFP)* larva showing connection (a'', arrowhead) of AF lymphatic sprout to the TD and CCL (a'', arrows). White dashed lines demarcate the developing AF; a'' depicts colocalization channel. b-d, Expression of *lyve1b:dsRed* through stages I-III of AF development shown along with *kdrl:GFP*+ BVC. Arrows in b point to the LVC sprouts at stage I. e-j, smFISH analysis of blood and lymphatic marker expression at stages I (e,f,h) and II (g) of AF development. e-h, *prox1a* mRNA puncta (magenta) are detected only in *mrc1a:GFP*+ LVC, while *fli1a* puncta (yellow) marks

both the *kdr1:GFP+* BVC and *mrc1a:GFP+* LVC (e,e',h). Blue dashed lines enclose the LVC and white box demarcates the insets shown in e'. Illustrations indicate the imaged ROI (black dashed box). I,j, Abundance of *prox1a* mRNA (i) and *fli1a* mRNA (j) ( $n_{AFs-LVC}=10$ ;  $n_{AFs-BVC}=12$ ) in LVC vs BVC. Boxes show 25th to 75th percentiles, line depicts median and whiskers show the full range of the data points. k-k'', Distribution of calcein in early stage III AF (k), following intramuscular injection in the trunk. k',k'', High-magnification of yellow box in k, showing calcein (green) within the lumen of a *prox1a+* LVC. Arrows point to the bony rays labeled by calcein. l-l', Hypoxyprobe staining in stage II AF (l) and its vehicle (PBS) injected control (l'). Yellow dashed lines indicate the area of the main lymphatic vessel in the AF. m,n, Stage IV AF in *prox1a* (m) and *mrc1a* (n) transgenic fish, whose colocalization channel is depicted in Fig. 1k. o, Intact *fli1a:dsRed+* vasculature is present in stage IV AFs. p,p', Intravascularly injected Qdot705 are detected in all vessels (*fli1a:dsRed+*) of the adult AF. Scale bars, 20  $\mu$ m (k,k',l,l'), 30  $\mu$ m (a,b,c), 50 $\mu$ m (d), 100 $\mu$ m (p,p'), 200 $\mu$ m (m), 500  $\mu$ m (o). TD, Thoracic duct, CCL, Collateral cardinal lymphatic, PCV, Posterior cardinal vein.






### Extended Data Fig. 3: A platform for long-term EC lineage tracing.

a, Schematic representation of the *flibow* construct used to drive expression of *brainbow* in ECs. Cre recombinase allows expression of different fluorescent proteins (*mCerulean* or *EYFP*) in non-recombinant (expressing *tdTomato*) animals. b, Schematic representation of the *hsp70l:CreERT2; flibow* lineage tracing protocol used in this study. c-g, Representative examples of induced recombination. Combined heat- and 4-OHT treatment allowed clear identification of 27 *larvae* (out of 54 screened) displaying differentially labelled ECs. c', Normalized intensity plotted across a range of emitted wavelength (x-axis) from 5 PCV-ECs


(c, numbered arrowheads), depicting how ECs display a unique spectral signature, based on the levels of expression of the 3 fluorophores. 4-OHT (d, 61/65) or heat treatment (e, 49/50) alone did not induce recombinant outcomes. d' and e' show 'spectral signatures' from 9 ECs from each group, demonstrating non-recombinant outcome depicted by the presence of tdTomato emission signal only. f, No recombination is detected in adult AFs treated with 4-OHT (22/22) or heat (g, 56/57) alone, and raised through adulthood. h-h'', Confocal images of *flibow larvae* showing distinct labeling of lymphatic components in the trunk starting from 24 hrs after Cre induction. h, ECs in the early TD of 3.5 dpf embryo labelled in green (arrowheads), are detected 24 hrs after heat and 4-OHT treatments. h'-h'', Reiterative imaging of the same embryo at 4.5 dpf (h') and 5.5 dpf (h'') shows the growing TD composed of green ECs (arrowheads). i-j', Assessment of the stability of the fluorophore ratios after Cre induction. i,i', Average normalized intensity from a 'switched' clonal population (n=4) measured at 24, 48 and 72 hours post treatment (hpt), showing slight deviation with time (i'). Intensities corresponding to each fluorophore are depicted separately for the 3 time-points and show a decay in tdTomato signal, that contributes to the deviation in the spectral signature shown in i. j,j', Similar measurements carried out on 'switched' clonal ECs from another sample at 16, 18, 22, 29 days post treatment (dpt), shows a negligible deviation between the channels (j), along with stable intensity proportions between the fluorophores (j'). Scale bars, 15  $\mu\text{m}$  (c), 30  $\mu\text{m}$  (d,e,h,h',h''), 300  $\mu\text{m}$  (f,g). PCV, Posterior Cardinal vein; DA, Dorsal Aorta; EC, endothelial cell; 4-OHT, 4-hydroxytamoxifen.



**Extended Data Fig. 4: Lineage tracing of BVC and LVC in growing AF.**


a, Summary of *hsp70l:CreER<sup>T2</sup>; flibow* experiments. b-c', Confocal images of *flibow* fish AF (Fish #26) showing a green labeled-blood vessel sprout generating the BVC in stage I AF (b,b', arrowhead, green). Clonally related ECs are detected in the dorso-anterior AF of the same animal at adult stages (c, arrowheads). Initial lymphatic sprout (b,b'', arrows, blue) in contrast, expands throughout the entire fin (c'). AF is demarcated by yellow dashed lines, asterisks in c indicate signal from unrelated non-EC autofluorescence. d-e, *Flibow* lineage tracing of BVC. Confocal images of the *kdr1:CreER<sup>T2</sup>; flibow* stage III (d) and adult AF (e) showing distinct labeling of BVC component near the trunk-fin junction (arrows). LVC-derived ray vessels display non-recombinant tdTomato signal. White dashed

box indicates region shown in the inset. The lack of fluorescent signal in the middle of AF is due to obstruction by the pigmented stripes in non-*casper* fish. f-f', Confocal images of the *kdr1:CreERT<sup>2</sup>;β-actin2:loxP-BFP-loxP-DsRed* adult AF showing contribution of BVC (arrows) to AF vasculature. When *kdr1:CreERT2* mediated recombination was induced between 3.5–5.5 dpf ( $n_{\text{switch line}}=40$ ,  $n_{\text{flibow}}=66$ ), 100% of the labeled clones found in the AF ( $n_{\text{switch line}}=10$ ,  $n_{\text{flibow}}=18$ ), were restricted to the BVC. Yellow dashed lines indicate the boundaries of the AF. Scale bars, 10 μm (b), 30 μm (d), 200 μm (c'), 300 μm (e,f).




**Extended Data Fig. 5: Loss of lymphatic fate is associated with elevated expression of blood EC markers.**

a-b, Scatterplot showing rlog expression of genes (a), in *PROX1* suppressed HDLECs, that are upregulated (dark green), downregulated (light green) or did not change significantly (grey). Genes of interest are annotated in the plot. Plots (b) showing mean normalized expression of selected genes upregulated following *PROX1* suppression in HDLECs (siPROX1). The box in the plots show 25th to 75th percentiles, the line shows the median and the whiskers show the full range of the data points. (\*\*\*\*, p-adj value<0.0001; \*\*\*, p-adj value<0.001; \*, p-value<0.05, Wald test). c-g, Confocal images of *Tg(sox17<sup>GFP</sup>)* showing expression of *sox17* across stages I-III AFs. c-c', Initially, no *sox17<sup>GFP</sup>* expression is detected in *lyve1b+* sprouts. d-g, Single GFP channel images of Fig 2h-k showing gradual enrichment of *sox17* expression. h-h', *flt1\_9a:EGFP* does not label *prox1a:RFP+* differentiated lymphatic vessels (TD) in 13 dpf larval trunk. i-j', Gradual increase of *flt1\_9a:EGFP* expression at stage III shown along with *lyve1b:dsRed+* (i) and *prox1a:RFP+* (j). Arrowheads in single GFP channel point to *flt1\_9a+* newly expressing ECs within the LVC plexus. k, Confocal image of *Tg(flt1:YFP)* showing specific expression in the BVC in early stage III AF (arrowheads). l-m'', Gradual expression of *kdr1* in *sox17<sup>GFP</sup>+* vessels of AF. l-l', LVC (*lyve1b:dsRed*) and BVC (*kdr1:BFP*) shown together along with transdifferentiated LVC-ECs (*sox17<sup>GFP</sup>*) in stage II AF. The transdifferentiating LVC-ECs (l', arrows) do not show expression of *kdr1*, which at this stage is restricted to BVC (l', arrowheads; l''). m-m', At the onset of stage IV (m), the growing *sox17<sup>GFP</sup>+* vessels, start expressing *kdr1* (m', arrows). BVC-ECs are *sox17<sup>GFP</sup>-* but *kdr1+* (m', arrowheads; m''). Scale bars, 30µm (h,c,l), 50µm (i,j), 100µm (k). TD, Thoracic duct.




**Extended Data Fig. 6: Expression of lymphatic and blood vessel-specific genes across the different scRNA-seq cell clusters.**

a-c, UMAP (shown in Fig. 2m) plots with embedded imputed expression of selected marker genes. a, Blood vessel markers specifically enriched in the BVC. b, Lymphatic markers specific for LEC cluster. c, Blood vessel markers enriched in LVC1 cluster (transdifferentiated LECs). d, Partition graph abstraction (PAGA) analysis of LVC clusters. e, UMAP showing the trajectory across the clusters (black line) following Slingshot analysis. f-g, PHATE (shown in Fig 2p) plots with embedded imputed expression of selected genes.



**Extended Data Fig. 7: *Sox17* misexpression results in suppression of lymphatic fate.** a-b', *sox17* misexpression results in loss of lymphatic marker expression in the AF. Stage IV AF (demarcated by yellow dashed lines) showing expression of *Lyve1b:dsRed*, at the dorsal trunk-fin junction of the AF (a), which is lost following mosaic expression of *UAS sox17* in *hsp70l:Gal4* animals (b, asterisks) (N=2, n=65). a', b' show the corresponding bright-light images. c, d, Confocal images of a 4.5 dpf *Tg(fli1a:Gal4; lyve1b:dsRed)* embryo showing the TD (c, arrowheads) that is lost (d, asterisks) following mosaic overexpression of *UAS sox17*. e-g, Confocal images of a 7 dpf *larva* with mosaic overexpression

of *UAS:sox17* in *Tg(fli1a:Gal4)* embryos showing complete (f, asterisks) or partial (g, arrowheads point to TD, asterisks denote absent TD segments) disruption in TD formation ( $N=2$ ,  $n_{\text{injected embryos}}=234$ ,  $n_{\text{uninjected embryos}}=87$ ). Scale bars, 20 $\mu\text{m}$  (c,d), 50 $\mu\text{m}$  (e,f,g), 100 $\mu\text{m}$  (a,b). TD, Thoracic duct; DA, Dorsal Aorta; PCV, Posterior cardinal vein.




**Extended Data Fig. 8: Different blood flow pattern and connectivity with the systemic circulation in WT and *fli4*<sup>-/-</sup> animals.**


a-b', Different tracers are readily detectable in the LVC of Stage III AFs. Distribution of Qdot705 (a,a', cyan) and FITC Dextran (MW= 500kDa) (b-b', yellow) in stage III AF.



LVC is labeled by *mrc1a/prox1a* colocalization (a,a', yellow) or *prox1a* (b, red); BVC is labeled by *kdrl* (blue) in b,b'. c-c', Appearance of *flt1\_9a:GFP* in the LVC (arrowheads) is detected in animals with intravascularly injected Qdot705 (cyan) before the tracer has entered the LVC compartment. Arrows point to BVC expression of *flt1\_9a:GFP*. d-e'. Early stages of AF development, before the connection between AF and DA is established, shown through *fli1a:dsRed* and *sox17<sup>GFP</sup>* expression analysis. d, *sox17+* ECs are not detected in stage I AF but are present in the trunk, near the DA. e-e', Stage II AF depicting *sox17+* sprouts (arrowheads) extending dorsally from the AF. DA-derived *sox17+* sprouts extend ventrally but remain within the trunk (arrow). f-h, Connection of LVC-derived plexus with the trunk vasculature is established through LVC sprouts that extend dorsally to reach the trunk. f-f', Stage II AF (f) show transdifferentiating LECs (*lyve1b+;sox17+*, arrowheads) sprouting dorsally towards the trunk. Arrow points to a trunk *sox17+* vessel that has not entered the AF. f' shows high magnification of single channel from f, to clearly depict the extending sprouts (arrowheads). g-g'', Microangiography with Qdot705 depicts patent connections established between the DA and stage III AF (not in the image) through a LVC-derived vessel (g',g'', *lyve1b+*, white arrowheads). h., Lineage tracing through Tg(*hsp70l:CreER<sup>T2</sup>;flibow*) animal depicting distinct labeling of BVC (crimson/violet mosaic, arrows) and LVC (green, arrowheads) and all their subsequent progenies. The LVC vessels sprout dorsally to connect with the trunk circulation. Scale bars, 20  $\mu\text{m}$  (c'), 30  $\mu\text{m}$  (d,e,f,g), 50  $\mu\text{m}$  (a,b).




**Extended Data Fig. 9: In absence of lymphatics the AF vasculature derives from trunk BECs.** a-a', Trunk lymphatics (*mrc1a*<sup>+</sup>, a) are absent in *flt4*<sup>-/-</sup> mutants (a'). The only *mrc1a*<sup>+</sup> structure visible in the trunk of *flt4*<sup>-/-</sup> is the PCV. b-e, The DF in *flt4*<sup>-/-</sup> mutants is vascularized by BECs. b-c, Early sprouting event in developing DFs in stage matched WT and *flt4*<sup>-/-</sup> animals, showing *lyve1b*<sup>+</sup> LVC sprouts in WT (b) that are missing in *flt4*<sup>-/-</sup> (c). d-e, Juvenile DF is fully vascularized by LVC in WT and BECs in *flt4*<sup>-/-</sup>. f-h, NTR-Mtz ablation of LVC in *Tg(prox1a:Gal4;UAS NTR-mCherry; kdr1:GFP)* animals, results in *kdr1*<sup>+</sup> BVC-derived vascularization of the AF (f), while DMSO (vehicle) treated animals develop a normal LVC-derived AF plexus (g,h). f-h, NTR-Mtz ablation of LVC in *Tg(prox1a:Gal4;UAS NTR-mCherry; kdr1:GFP)* animals, results in *kdr1*<sup>+</sup> BVC-derived vascularization of the AF (f), while DMSO (vehicle) treated animals develop a normal LVC-derived AF plexus (g,h). f shows the status of *kdr1*<sup>+</sup> vessels in the AF, 3 days post first Mtz treatment. The vehicle treated AFs are shown at 5 days (g) and 15 days (h) after the first DMSO treatment. i-j, Lineage analysis of AF ECs in *flt4*<sup>-/-</sup>; *hsp70l:CreERT2*; *flibow* fish (Fish #A). i, Stage I AF of *flt4*<sup>-/-</sup>; *hsp70l:CreERT2*; *flibow* fish (Fish #A) showing distinctly labeled clones (green, arrowheads) in BVC (connected to PCV and cloacal vessels). j, Adult AF vasculature of the same fish shown in i, bears clones of matching identity (arrowheads). Scale bars, 30 μm (c,f), 40 μm (g), 50 μm (a,a',b,d,e,h,i), 300 μm (j).



**Extended Data Fig. 10: Functional characterization of AF vessels in WT and *flt4*<sup>-/-</sup>.**

a,b, Differential erythrocyte flow in WT vs. *flt4*<sup>-/-</sup> animals. Bright-light intensity profile from the lumen of fin ray vessels in WT (a) or *flt4*<sup>-/-</sup> (b) fish ( $n_{WT}=3$ ,  $n_{flt4^{-/-}}=3$ ) showing different modes of erythrocyte flow in WT (no flow, intermittent flow, continuous flow) (a), vs. continuous erythrocyte flow in *flt4*<sup>-/-</sup> mutants (b). c, Quantification of erythrocyte-mediated intensity change (spikes) events ( $n_{WT}=10$ ,  $n_{flt4^{-/-}}=9$ ). d-e, Differences in erythrocyte flow in WT vs. *flt4*<sup>-/-</sup> juvenile fish (stage IV). Bright-light intensity profile (d) from the lumen of fin ray vessels in WT vs *flt4*<sup>-/-</sup> are shown, along with the

quantification of erythrocyte-mediated intensity change (spikes) events (e) ( $n_{wt}=6$ ;  $n_{flt4^{-/-}}=4$ ). The box in the plots (c,e) show 25th to 75th percentiles, the line in the middle shows the median and the whiskers show the full range of the data points. f-h", Confocal imaging of erythrocytes in the AF is shown with *gata1a:dsRed*, in the background of pan-endothelial *fli1a:GFP*. k-l, Confocal images of entire AFs, showing *gata1a+* cells majorly accumulated in the anterior BVC in WT animals (f, arrow), as opposed to widespread distribution of *gata1a+* cells in all AF vessels (g) in *flt4^{-/-}*. h-h", High magnification images of single rays from f and g depicting the presence or absence of *gata1a+* cells inside the lumen of WT LVC derived AF ray vessels (h), WT BVC vessels (h') and *flt4^{-/-}* AF ray vessels (h"). i, Schematic illustration of the different functional properties of AF vessels originating via LEC transdifferentiation vs. BEC angiogenesis. j, 3D rendered image of a  $\mu$ CT scan of adult AF, showing the external rays (white) and the internal radials (green). k, Cross-section of the radials depicting the size and morphological defects (arrowhead) detected in *flt4^{-/-}* as compared to WT siblings. Yellow dashed lines enclose one set of radials. l, Quantification of the MR length is plotted ( $n_{wt}=15$ ;  $n_{flt4^{-/-}}=15$ ). Scale bars, 300  $\mu$ m (f,g). \*\*\* $p<0.0005$ .



**Extended Data Fig. 11: Lineage tracing of regenerating AF vasculature.**

a-b, *mrc1a:EGFP* labeled LVC growth along *osx:mCherry* labeled bones, as detected in 5 dpa (a) and 7 dpa (a', a'') AFs. Inset (a'') shows *mrc1a* channel only to visualize the LECs (arrowheads) growing along a single regenerating ray. b, Status and extent of BVC (*kdr1:EGFP+*, arrowheads) coverage in a 5 dpa regenerating AF shown in contrast to LVC (*prox1a:RFP+*). c, *flt1\_9a:GFP* expression is detected in *prox1a:RFP+* LECs of the regenerating AF plexus at 4 dpa (arrowheads). d-e, Clonal identity of AF vessels before and after regeneration traced in the same animal. d, Dissected AF from an adult *hsp70l:CreER<sup>T2</sup>; flibow* fish, showing distinctly labelled clones (green) throughout the fin except for the anterior-most rays. e, Regenerated AF in same fish shown in d, at 20 dpa. ECs of same clonal identity (green), populate the regenerating vasculature recapitulating the distribution seen in d. f, Proportion of new clones (blue) in AF regenerated vascular plexus under different experimental setups. No YFP/mCerulean expression was detected in the uninduced controls during the regeneration process ( $n_{\text{heat-shock only}}=29$ ;  $n_{4\text{-OHT only}}=32$ ).

g, Regenerated AF in adult *kdrl:CreER<sup>T2</sup>; flibow* fish at 20dpa, shows distinctly labeled BVC (arrowheads) at the anterior trunk-fin junction of the AF. Scale bars, 20  $\mu\text{m}$  (c), 100  $\mu\text{m}$  (a,a”), 300  $\mu\text{m}$  (g), 500  $\mu\text{m}$  (d,e). dpa, days post amputation.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

The authors thank Hila Raviv, Lital Shen, Dean Robinson and Aryeh Solomon (Weizmann Institute, Israel) for technical assistance, Kamalesh Kumari (Weizmann Institute, Israel) for assistance with image analysis and illustrations, Gabriella Almog, Roy Hofi, Alla Glozman and Anna Tatarin (Weizmann Institute, Israel) for superb animal care, Moshe Biton (Weizmann Institute, Israel) for critical insights into single cell RNASeq analyses and Sergey Kapishnikov for assistance with  $\mu\text{CT}$  experiments. The authors are grateful to all the members of the Yaniv lab for discussion, technical assistance and continuous support. This work was supported in part by European Research Council (818858) to KY, Minerva Foundation (712610) to KY, and the H&M Kimmel Inst. for Stem Cell Research (Weizmann Institute) and the Estate of Emile Mimran (SABRA program) to KY. KY is the incumbent of the Enid Barden and Aaron J. Jade Professorial Chair and is supported by research grants from Madame Olga Klein – Astrachan and the Estate of Mady Dukler. RND was supported by EMBO long-term fellowship (ALTF 1532–2015), Edith and Edward F. Anixter Postdoctoral Fellowship and a senior postdoctoral fellowship by the Weizmann Institute of Science. WH was supported by the Deutsche Forschungsgemeinschaft (HE4585/4–1) and by the North Rhine-Westphalia “return fellowship”. RA is supported by the European Research Council (756653) and the Israel Science Foundation (1890/17). KDP acknowledges support from National Institutes of Health (R35 HL150713, R01 HD105033).

## References


1. Augustin HG & Koh GY Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology. *Science* 357, (2017).
2. Petrova TV & Koh GY Organ-specific lymphatic vasculature: From development to pathophysiology. *J. Exp. Med.* 215, 35–49 (2018). [PubMed: 29242199]
3. Semo J, Nicenboim J & Yaniv K Development of the lymphatic system: new questions and paradigms. *Development* 143, 924–35 (2016). [PubMed: 26980792]
4. Gutierrez-Miranda L & Yaniv K Cellular Origins of the Lymphatic Endothelium: Implications for Cancer Lymphangiogenesis. *Front. Physiol.* 11, 577584 (2020). [PubMed: 33071831]
5. Parichy DM, Elizondo MR, Mills MG, Gordon TN & Engeszer RE Normal table of postembryonic zebrafish development: staging by externally visible anatomy of the living fish. *Dev Dyn* 238, 2975–3015 (2009). [PubMed: 19891001]
6. Marí-Beffa M & Murciano C Dermoskeleton morphogenesis in zebrafish fins. *Dev. Dyn.* 239, 2779–2794 (2010). [PubMed: 20931648]
7. Vogel WOP & Claviez M Vascular Specialization in Fish, but No Evidence for Lymphatics. *Z. Für Naturforschung C* 36, 490–492 (1981).
8. Steffensen JF, Lomholt JP & Vogel WOP. In vivo Observations on a Specialized Microvasculature, the Primary and Secondary Vessels in Fishes. *Acta Zool.* 67, 193–200 (1986).
9. Olson KR Secondary circulation in fish: Anatomical organization and physiological significance. *J. Exp. Zool.* 275, 172–185 (1996).
10. Jensen LDE et al. Nitric oxide permits hypoxia-induced lymphatic perfusion by controlling arterial-lymphatic conduits in zebrafish and glass catfish. *Proc. Natl. Acad. Sci.* 106, 18408–18413 (2009). [PubMed: 19822749]
11. Rummer JL, Wang S, Steffensen JF & Randall DJ Function and control of the fish secondary vascular system, a contrast to mammalian lymphatic systems. *J. Exp. Biol.* 217, 751–757 (2014). [PubMed: 24198251]

12. Karpanen T & Schulte-Merker S Chapter 9 - Zebrafish Provides a Novel Model for Lymphatic Vascular Research. in *Methods in Cell Biology* (eds. Detrich HW, Westerfield M & Zon LI) vol. 105 223–238 (Academic Press, 2011). [PubMed: 21951532]
13. Jung HM et al. Development of the larval lymphatic system in zebrafish. *Development* 144, 2070–2081 (2017). [PubMed: 28506987]
14. Gancz D, Perlmoter G & Yaniv K Formation and Growth of Cardiac Lymphatics during Embryonic Development, Heart Regeneration, and Disease. *Cold Spring Harb. Perspect. Biol.* (2019) doi:10.1101/cshperspect.a037176.
15. Potente M & Makinen T Vascular heterogeneity and specialization in development and disease. *Nat Rev Mol Cell Biol* 18, 477–494 (2017). [PubMed: 28537573]
16. Yaniv K et al. Live imaging of lymphatic development in the zebrafish. *Nat Med* 12, 711–6 (2006). [PubMed: 16732279]
17. Dunwoodie SL The role of hypoxia in development of the Mammalian embryo. *Dev. Cell* 17, 755–773 (2009). [PubMed: 20059947]
18. Akiva A et al. On the pathway of mineral deposition in larval zebrafish caudal fin bone. *Bone* 75, 192–200 (2015). [PubMed: 25725266]
19. Bennet M et al. Simultaneous Raman microspectroscopy and fluorescence imaging of bone mineralization in living zebrafish larvae. *Biophys J* 106, L17–9 (2014). [PubMed: 24560001]
20. Zhao L et al. Notch signaling regulates cardiomyocyte proliferation during zebrafish heart regeneration. *Proc Natl Acad Sci U A* 111, 1403–8 (2014).
21. Kobayashi I et al. Jam1a – Jam2a interactions regulate haematopoietic stem cell fate through Notch signalling. *Nature* 512, 319–323 (2014). [PubMed: 25119047]
22. Johnson NC et al. Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. *Genes Dev.* (2008) doi:10.1101/gad.1727208.
23. Ma W & Oliver G Lymphatic Endothelial Cell Plasticity in Development and Disease. *Physiology* 32, 444–452 (2017). [PubMed: 29021364]
24. Chen C-Y et al. Blood flow reprograms lymphatic vessels to blood vessels. *J. Clin. Invest.* 122, 2006–2017 (2012). [PubMed: 22622036]
25. Chen J et al. Acute brain vascular regeneration occurs via lymphatic transdifferentiation. *Dev. Cell* S1534–5807(21)00723–1 (2021) doi:10.1016/j.devcel.2021.09.005.
26. Kim J et al. Impaired angiopoietin/Tie2 signaling compromises Schlemm’s canal integrity and induces glaucoma. *J. Clin. Invest.* 127, 3877–3896. [PubMed: 28920924]
27. Corada M et al. Sox17 is indispensable for acquisition and maintenance of arterial identity. *Nat. Commun.* (2013) doi:10.1038/ncomms3609.
28. Gancz D et al. Distinct origins and molecular mechanisms contribute to lymphatic formation during cardiac growth and regeneration. *eLife* (2019) doi:10.7554/eLife.44153.
29. Nicenboim J et al. Lymphatic vessels arise from specialized angioblasts within a venous niche. *Nature* 522, 56–61 (2015). [PubMed: 25992545]
30. Hen G et al. Venous-derived angioblasts generate organ-specific vessels during zebrafish embryonic development. *Dev. Camb. Engl.* 142, 4266–4278 (2015).
31. Keren-Shaul H et al. MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing. *Nat Protoc* 14, 1841–1862 (2019). [PubMed: 31101904]
32. Moon KR et al. Visualizing structure and transitions in high-dimensional biological data. *Nat. Biotechnol.* 37, 1482–1492 (2019). [PubMed: 31796933]
33. Street K et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. *BMC Genomics* 19, 477 (2018). [PubMed: 29914354]
34. Wolf FA et al. PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. *Genome Biol.* 20, 59 (2019). [PubMed: 30890159]
35. Harikumar A et al. Embryonic Stem Cell Differentiation Is Regulated by SET through Interactions with p53 and  $\beta$ -Catenin. *Stem Cell Rep.* 15, 1260–1274 (2020).
36. Zhou X et al. HMGB2 regulates satellite-cell-mediated skeletal muscle regeneration through IGF2BP2. *J. Cell Sci.* 129, 4305–4316 (2016). [PubMed: 27672022]

37. Garza-Manero S et al. Maintenance of active chromatin states by HMG2 is required for stem cell identity in a pluripotent stem cell model. *Epigenetics Chromatin* 12, 73 (2019). [PubMed: 31831052]
38. Bao X et al. CSNK1a1 Regulates PRMT1 to Maintain the Progenitor State in Self-Renewing Somatic Tissue. *Dev. Cell* 43, 227–239.e5 (2017). [PubMed: 28943242]
39. Jerafi-Vider A et al. VEGFC/FLT4-induced cell-cycle arrest mediates sprouting and differentiation of venous and lymphatic endothelial cells. *Cell Rep.* 35, 109255 (2021). [PubMed: 34133928]
40. Shin M et al. Vegfc acts through ERK to induce sprouting and differentiation of trunk lymphatic progenitors. *Development* 143, 3785–3795 (2016). [PubMed: 27621059]
41. Singh SP, Holdway JE & Poss KD Regeneration of Amputated Zebrafish Fin Rays from De Novo Osteoblasts. *Dev. Cell* 22, 879–886 (2012). [PubMed: 22516203]
42. Silvent J et al. Zebrafish skeleton development: High resolution micro-CT and FIB-SEM block surface serial imaging for phenotype identification. *PLoS One* 12, e0177731 (2017). [PubMed: 29220379]
43. Das RN & Yaniv K Discovering New Progenitor Cell Populations through Lineage Tracing and In Vivo Imaging. *Cold Spring Harb. Perspect. Biol.* a035618 (2020) doi:10.1101/cshperspect.a035618.
44. Vogel WOP Zebrafish and lymphangiogenesis: a reply. *Anat. Sci. Int.* 85, 118–119 (2010). [PubMed: 20232268]
45. Gur-Cohen S et al. Stem cell-driven lymphatic remodeling coordinates tissue regeneration. *Science* 366, 1218 LP–1225 (2019). [PubMed: 31672914]
46. Louveau A et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. *Nat. Neurosci.* 21, 1380–1391 (2018). [PubMed: 30224810]
47. Da Mesquita S et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. *Nature* (2018) doi:10.1038/s41586-018-0368-8.
48. Pavlov V et al. Hydraulic control of tuna fins: A role for the lymphatic system in vertebrate locomotion. *Science* (2017) doi:10.1126/science.aak9607.
49. Oliver G, Kipnis J, Randolph GJ & Harvey NL The Lymphatic Vasculature in the 21st Century: Novel Functional Roles in Homeostasis and Disease. *Cell* 182, 270–296 (2020). [PubMed: 32707093]
50. Pawlak JB et al. Lymphatic mimicry in maternal endothelial cells promotes placental spiral artery remodeling. *J. Clin. Invest.* 129, 4912–4921. [PubMed: 31415243]
51. Song E et al. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. *Nature* 577, 629–630 (2020). [PubMed: 31988406]
52. Jin S-W, Beis D, Mitchell T, Chen J-N & Stainier DYR Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. *Development* 132, 5199 LP–5209 (2005). [PubMed: 16251212]
53. Matsuoka RL et al. Radial glia regulate vascular patterning around the developing spinal cord. *eLife* 5,.
54. Spoorendonk KM et al. Retinoic acid and Cyp26b1 are critical regulators of osteogenesis in the axial skeleton. *Development* 135, 3765–3774 (2008). [PubMed: 18927155]
55. Shin J, Poling J, Park H-C & Appel B Notch signaling regulates neural precursor allocation and binary neuronal fate decisions in zebrafish. *Development* 134, 1911–1920 (2007). [PubMed: 17442701]
56. Davison JM et al. Transactivation from Gal4-VP16 transgenic insertions for tissue-specific cell labeling and ablation in zebrafish. *Dev. Biol.* 304, 811–824 (2007). [PubMed: 17335798]
57. Avraham-Davidi I et al. ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1. *Nat Med* 18, 967–73 (2012). [PubMed: 22581286]
58. White RM et al. Transparent Adult Zebrafish as a Tool for In Vivo Transplantation Analysis. *Cell Stem Cell* 2, 183–189 (2008). [PubMed: 18371439]
59. Villefranc JA, Amigo J & Lawson ND Gateway compatible vectors for analysis of gene function in the zebrafish. *Dev Dyn* 236, 3077–87 (2007). [PubMed: 17948311]




60. Hesselson D, Anderson RM, Beinat M & Stainier DY Distinct populations of quiescent and proliferative pancreatic beta-cells identified by HOTcre mediated labeling. *Proc Natl Acad Sci U S A* 106, 14896–901 (2009).
61. Suster ML, Abe G, Schouw A & Kawakami K Transposon-mediated BAC transgenesis in zebrafish. *Nat. Protoc.* 6, 1998–2021 (2011). [PubMed: 22134125]
62. Dahlem TJ et al. Simple Methods for Generating and Detecting Locus-Specific Mutations Induced with TALENs in the Zebrafish Genome. *PLOS Genet.* 8, e1002861 (2012). [PubMed: 22916025]
63. Han Y et al. Vitamin D Stimulates Cardiomyocyte Proliferation and Controls Organ Size and Regeneration in Zebrafish. *Dev. Cell* 48, 853–863.e5 (2019). [PubMed: 30713073]
64. Oehlers SH et al. Interception of host angiogenic signalling limits mycobacterial growth. *Nature* 517, 612–615 (2015). [PubMed: 25470057]
65. Lyubimova A et al. Single-molecule mRNA detection and counting in mammalian tissue. *Nat. Protoc.* 8, 1743–1758 (2013). [PubMed: 23949380]
66. Schindelin J et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* 9, 676–682 (2012). [PubMed: 22743772]
67. Love MI, Huber W & Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550 (2014). [PubMed: 25516281]
68. Zhu A, Ibrahim JG & Love MI Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. *Bioinformatics* 35, 2084–2092 (2019). [PubMed: 30395178]
69. Hoffman D et al. A non-classical monocyte-derived macrophage subset provides a splenic replication niche for intracellular Salmonella. *Immunity* 54, 2712–2723.e6 (2021). [PubMed: 34788598]
70. Manco R et al. Clump sequencing exposes the spatial expression programs of intestinal secretory cells. *Nat. Commun.* 12, 3074 (2021). [PubMed: 34031373]
71. Kult S et al. Bi-fated tendon-to-bone attachment cells are regulated by shared enhancers and KLF transcription factors. *eLife* 10, e55361 (2021). [PubMed: 33448926]
72. McFarland AP et al. Multi-tissue single-cell analysis deconstructs the complex programs of mouse natural killer and type 1 innate lymphoid cells in tissues and circulation. *Immunity* 54, 1320–1337.e4 (2021). [PubMed: 33945787]
73. Satija R, Farrell JA, Gennert D, Schier AF & Regev A Spatial reconstruction of single-cell gene expression data. *Nat. Biotechnol.* 33, 495–502 (2015). [PubMed: 25867923]
74. van Dijk D et al. Recovering Gene Interactions from Single-Cell Data Using Data Diffusion. *Cell* 174, 716–729.e27 (2018). [PubMed: 29961576]
75. Wolf FA, Angerer P & Theis FJ SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol.* 19, 15 (2018). [PubMed: 29409532]




**Fig. 1: Stepwise formation of the AF vasculature.**

a-a', Illustrations of adult zebrafish depicting the location of the anal (AF, blue box) dorsal (DF) and caudal (CF) fins (a), and general skeletal structure (a'). Red arrowhead points to internal (endochondral) radial bones, blue arrowhead marks external dermal bones (rays) of AF. b, *fli1a*:*dsRed*+ ECs are not detected in the median fin fold (demarcated by green dashed line) prior to the initiation of AF development (Stage 0). c-h', Formation of vascular and bony structures during AF formation – stage I (c-d), stage II (e,f), stage III (g-h'). LVC is labeled by *prox1a/mrc1a* colocalization (c,c',f,g, yellow) or *mrc1a*:*GFP* (d,e,h,h', green); blood vessels are highlighted by *kdr1*:*BFP* (c,c',f,g, blue) and osteoblasts by *osx*:*mCherry* (d,e,h, red). Arrowheads in (c) point to anterior and posterior lymphatic sprouts; arrows in (c,f) point to AF BVC. h', high magnification of single ray (yellow dashed box in (h)) depicting associated LVC. i, Schematic illustrating the development of LVC (yellow), BVC (blue) and bony (white) components of the AF. j-j', Intravascularly injected Qdot705 are detected in *kdr1*:*GFP*+ BVC (arrows) of stage II AF, but not in *lyve1b*:*dsRed* labelled LVC (red). k-m, Lymphatic markers are lost in stage IV AFs (AF boundaries demarcated by white dots), as depicted by *prox1a/mrc1a* co-localization channel (k, yellow) and *mrc1a*:*GFP* (l, green) expression. Intact *fli1a*:*dsRed*+ vasculature is present in stage IV AFs (l, red). m, Lymphatic vessels (*lyve1b*) are absent from adult AFs. Scale bars, 30 mm (c,c',h,h',j), 50mm (b,d,e,f,g), 100 $\mu$ m (l), 150 $\mu$ m (k). LVC, Lymphatic vascular component, BVC, Blood vascular component, PCV, Posterior cardinal vein, cl, Cloaca.



**Fig. 2: Lymphatic vessels give rise to the adult AF vasculature via transdifferentiation.**  
 a-e, Confocal imaging of the same *hsp70l:CreERT<sup>2</sup>; flibow* fish (Fish #1) every 24–72 hrs, showing generation of AF vessels from trunk lymphatics. TD-derived green ECs (a, arrowheads) penetrate the AF (b, stage I), and grow ventrally to generate the anterior half of the AF plexus as seen in stages II (c), III (d) and IV (e). The posterior unlabeled AF sprout (c, non-recombinant tdTomato (red), arrow), results in unlabeled posterior half of mature AF (d,e; red). f-g, Confocal images of *hsp70l:CreERT<sup>2</sup>; flibow* (Fish #2) showing the entire AF vasculature at 3 mpf (g, blue) derives from Stage I clonally related LECs (f, lymphatic arc, blue). h-k, Progressive enrichment of *sox17<sup>EGFP</sup>* expression across stages I to III. l-l'', *flt1\_9a:EGFP* strongly labels the BVC (l, arrows) and is upregulated in individual *lyve1:dsRed+* LECs (arrowheads) of the early LVC. l', l'' show high magnification of blue ROI in l. m, UMAP of 632 ECs isolated from stage II/III AFs, depicting 5 cell clusters: BVC (purple, 191 cells), LEC (blue, 71 cells), LVC1 (green, 149 cells), LVC2 (red, 185 cells). The 'non-EC' cluster (grey, 36 cells) was discarded from further analyses. n, Heatmap indicating the relative expression (yellow=high; purple=low) of DEGs per cluster, genes of interest are annotated. o, Dot plot depicting scaled expression of genes of interest in each cluster. The size of the dots corresponds to % of expressing cells within the cluster. p, Three clusters composing the LVC – LEC, LVC1, LVC2– are visualized using PHATE, and color coded in accordance to the clusters shown in m. Scale bars, 15  $\mu$ m (a,l'), 20  $\mu$ m (b), 30  $\mu$ m (c,f,l), 50  $\mu$ m (d,j,k), 100  $\mu$ m (e), 300  $\mu$ m (g).



**Fig. 3: The functional specialization of AF vessels is linked to their cellular origins.**

a-b', AF LVC forms patent connections with systemic circulation at stage III. Distribution of intravascularly injected Rhodamine dextran (MW=2000 kDa) in stage II (a-a') and III (b-b') AFs, shown along with LVC (*mrc1a:EGFP+*) and BVC (*kdr1:BFP+*). Blood-borne tracer (red) is seen in the lumen of *mrc1a+* vessels in stage III but not in stage II AFs. c-c', Lymphatic transdifferentiation occurs before the LVC connects to blood flow. *sox17*<sup>GFP</sup> expression is detected in the LVC (arrowheads) before the intravascularly injected Qdot705 (cyan) enter the LVC compartment (c'). All vessels in c are labeled with *fli1a:dsRed*. (d) Confocal image (also shown in Fig. 2j), depicting the connection between the AF and the trunk blood vasculature mediated through *sox17*<sup>GFP+</sup> vessels. e-i, Lack of lymphatics induces blood vessel-derived vascularization of the AF. Stage II AF of *flt4*<sup>-/-</sup> lacks *lyve1b:dsRed*+ LVC (f), that is present in WT siblings (e, red). *kdr1:GFP*+ BVC is detected in both (e,f, green). Arrowheads in f point to the connections with cloacal vessels and PCV. Stage III WT AF is primarily vascularized by LVC-derivatives (g, *lyve1b:dsRed*), whereas only BVC-derived vessels are detected in AFs of *flt4*<sup>-/-</sup> (h, *kdr1:GFP*). i, Status of BVC-derived vessels (*kdr1:GFP*), 22 days post NTR-Mtz mediated ablation of LVC in Tg(*prox1a:Gal4;UAS:NTR-mCherry*) animals. Arrows point to small patches of *prox1a+* LVC cells that escaped ablation. j-j', *flt4*<sup>-/-</sup> mature AF display erythrocyte pooling (j', arrowheads, n=10) as opposed to WT siblings. k, Comparison of radial morphology between WT and *flt4*<sup>-/-</sup> animals, revealing major defects in the MR. q, Radials have been magnified and color coded to reveal the three segments – PR, MR and DR, of the WT (left) and


*flt4<sup>-/-</sup>* (right). Scale bars, 30  $\mu\text{m}$  (a,b,c), 50  $\mu\text{m}$  (d,e,f,g,h,j), 100  $\mu\text{m}$  (i), 300  $\mu\text{m}$  (k).  
NTR, Nitroreductase, Mtz, Metronidazole,  $\mu\text{CT}$ , Micro-computed tomography, PR, Proximal radial, MR, Medial Radial, DR, Distal Radial.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Fig. 4: Vasculization of regenerating AFs recapitulates developmental programs.**

a, Schematic representation of AF regeneration protocol. a', Adult AF depicting the plane of amputation at the level of the trunk-fin junction (white dotted line), and the unamputated residual lymphatics (arrowheads). b, Expression of *mrc1a:EGFP* in vessels re-vascularizing the regenerating AF (arrowheads ventral to the white dashed line) at 5 dpa. Arrows point to residual lymphatics in unamputated area. c-c'', *sox17<sup>EGFP</sup>* expression is upregulated in 6 dpa regenerated AF vasculature (highlighted by *fli1a:dsRed*). Insets (c', c'') show high magnification of blue box ROI. d-e, *mrc1a:EGFP* is gradually lost from regenerating AF vessels (d, 13 dpa; e, 50 dpa). f, Schematic representation of protocol for lifetime lineage tracing of AF vasculature in (*hsp70l:CreERT<sup>2</sup>; flibow*) animals. g-k, Lymphatic clones (green, arrowheads) detected in the TD (g) sprout into the developing AF (h). i, Status of same clones at stage IV. j, Dissected adult AF displays ECs of same clonal identity as g and h. k, Vasculature of 20 dpa regenerated AF of same fish shown in g-j, depicting the distribution of ECs of same clonal identity (green). Scale bars, 30  $\mu\text{m}$  (g,h), 50  $\mu\text{m}$  (b), 100  $\mu\text{m}$  (c,c''), 150  $\mu\text{m}$  (i), 300  $\mu\text{m}$  (d,j,k), 500  $\mu\text{m}$  (e). dpa, days post amputation.